Details of the Drug

General Information of Drug (ID: DMYLMU0)

Drug Name
Isosorbide Mononitrate
Synonyms
Conpin; Corangin; Duride; Edistol; Elantan; Epicordin; Etimonis; IHD; ISMN; ISMO; Imazin; Imdur; Imodur; Imtrate; Ismexin; Ismox; Isomon; Isomonat; Isomonit; Iturol; Medocor; Monicor; Monis; Monisid; Monit; Monizid; MonoSigma; Monocedocard; Monocinque; Monoclair; Monocord; Monoket; Monolong; Monomax; Mononit; Monopront; Monosorb; Monosorbitrate; Monosordil; Monotrate; Multitab; Nitex; Nitramin; Olicard; Olicardin; Orasorbil; Percorina; Pertil; Plodin; Promocard; Sigacora; Sorbimon; Titarane; Turimonit; Uniket; Vasdilat; Vasotrate; Conpin Retardkaps; Corangin SR; Elantan Long; Elantan Retard; ISMN AL; ISMN AbZ; ISMN Apogepha; ISMN Atid; ISMN Basics; ISMN Heumann; ISMN Hexal; ISMN Lannacher; ISMN Stada; Imdur Durules; Isosorbidi mononitras; Isosorbidi mononitras [Latin]; Mono Corax; Mono Corax Retard; Mono Mack; Monodur Durules; Monoket OD; Monoket Retard; Mononitrato de isosorbida; Mononitrato de isosorbida [Spanish]; AHR 4698; IS 5MN; Imdur 60; Monit 20; Mono Mac 50D; Monocord 20; Monocord 40; Monocord 50 SR; Monolong 40; Monolong 60; Mononit 20; Mononit 40; Mononit Retard 50; Monosorb XL 60;Olicard 40; Pentacard 20; AHR-4698; BM 22-145; BM 22.145; Chemydur (TN); Fem-Mono; IS 5-MN; Imdur (TN); Ismo (TN); Ismo-20; Isopen-20; Isosorbide 5-mononitrate; Isosorbide 5-nitrate; Mono-Mack; Mono-Sanorania; Mononitrate d'isosorbide; Mononitrate d'isosorbide [French]; Olicard-retard; BM-22-145; Isosobide-5-mononitrate [UN3251] [Flammable solid]; Isosorbide-5-mononitrate; Isosorbide-5-nitrate; Isosorbide mononitrate (JAN/USP/INN); Isosorbide mononitrate [USAN:BAN:INN:JAN]; Isosorbide mononitrate [USAN:INN:BAN:JAN]; D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate; [(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3,6-Dianhydro-D-glucitol 5-nitrate; 1,4:3,6-dianhydro-5-O-nitro-D-glucitol; 5-ISMN Durules; 5-Ismn
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [1]
Hydrocephalus 8D64 Approved [2]
Therapeutic Class
Vasodilator Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 191.14
Logarithm of the Partition Coefficient (xlogp) -0.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 40% [4]
Clearance
The total body clearance of drug is 115-120 mL/min [5]
Elimination
In a human radio-labelled drug study, about 93% of the total dose was excreted in the urine within 48 hours [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 hours [6]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.9688 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 1% [8]
Vd
The volume of distribution (Vd) of drug is 0.6 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 1.1 mg/mL [3]
Chemical Identifiers
Formula
C6H9NO6
IUPAC Name
[(3S,3aR,6R,6aS)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
Canonical SMILES
C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O
InChI
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
InChIKey
YWXYYJSYQOXTPL-SLPGGIOYSA-N
Cross-matching ID
PubChem CID
27661
ChEBI ID
CHEBI:6062
CAS Number
16051-77-7
DrugBank ID
DB01020
TTD ID
D0YS7D
INTEDE ID
DR0889
ACDINA ID
D00334
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Guanylate cyclase (GC) TT6HPVC NOUNIPROTAC Stimulator [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Isosorbide Mononitrate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Cariprazine. Bipolar disorder [6A60] [11]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Selegiline. Depression [6A70-6A7Z] [12]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Isocarboxazid. Depression [6A70-6A7Z] [12]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and OPC-34712. Depression [6A70-6A7Z] [11]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Procarbazine. Hodgkin lymphoma [2B30] [12]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Captopril. Hypertension [BA00-BA04] [13]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and ITI-007. Insomnia [7A00-7A0Z] [11]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Ozanimod. Multiple sclerosis [8A40] [12]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Promethazine. Nausea/vomiting [MD90] [11]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Safinamide. Parkinsonism [8A00] [12]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Rasagiline. Parkinsonism [8A00] [12]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Levomepromazine. Psychotic disorder [6A20-6A25] [11]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Quetiapine. Schizophrenia [6A20] [11]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Aripiprazole. Schizophrenia [6A20] [11]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Iloperidone. Schizophrenia [6A20] [11]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Paliperidone. Schizophrenia [6A20] [11]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Molindone. Schizophrenia [6A20] [11]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Thiothixene. Schizophrenia [6A20] [11]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Amisulpride. Schizophrenia [6A20] [11]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Asenapine. Schizophrenia [6A20] [11]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Isosorbide mononitrate and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [14]
⏷ Show the Full List of 21 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Aluminum stearate E00218 12496 Emollient; Emulsion stabilizing agent; Opacifying agent; Viscosity-controlling agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate E00244 15324 lubricant
Dibasic ammonium phosphate E00305 44134541 Buffering agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Isosorbide 10mg tablet 10mg Tablet Oral
Isosorbide mononitrate 120 mg tablet 120 mg 24 HR Extended Release Oral Tablet Oral
Isosorbide mononitrate 30 mg tablet 30 mg 24 HR Extended Release Oral Tablet Oral
Isosorbide mononitrate 60 mg tablet 60 mg 24 HR Extended Release Oral Tablet Oral
Isosorbide mononitrate 60 mg tablet 60 mg 24 HR Extended Release Tablet Oral
Isosorbide mononitrate 10 mg tablet 10 mg Oral Tablet Oral
Isosorbide mononitrate 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Isosorbide mononitrate FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 BDDCS applied to over 900 drugs
4 Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990 Oct;19(4):264-79. doi: 10.2165/00003088-199019040-00002.
5 Abshagen UW: Pharmacokinetics of isosorbide mononitrate. Am J Cardiol. 1992 Nov 27;70(17):61G-66G. doi: 10.1016/0002-9149(92)90028-w.
6 FDA Approved Drug Products: Monoket (isosorbide mononitrate) tablets
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
10 Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
11 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
12 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
13 Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
14 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.